Multiple Catalysts Ahead For Nektar Therapeutics
Nektar continues to make progress with rezpegaldesleukin, with results from phase 2 atopic dermatitis study expected in H1'25 ...
Nektar Therapeutics (NASDAQ:NKTR) Just Reported And Analysts Have Been Lifting Their Price Targets
Nektar Therapeutics ( NASDAQ:NKTR ) investors will be delighted, with the company turning in some strong numbers ...
Nektar Therapeutics Reports Stable Q3 Earnings for 2024
Nektar Therapeutics ( (NKTR) ) has released its Q3 earnings. Here is a breakdown of the information Nektar Therapeutics presented to its ...
Seeking Alpha6d
Nektar Therapeutics (NKTR) Q3 2024 Earnings Call Transcript
Good day and thank you for standing by. Welcome to the Nektar Therapeutics' Third Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
ETF Daily News6d
Nektar Therapeutics (NASDAQ:NKTR) Coverage Initiated at Piper Sandler
Piper Sandler assumed coverage on shares of Nektar Therapeutics (NASDAQ:NKTR – Free Report) in a research note released on Monday, Marketbeat Ratings reports. The brokerage issued an overweight ...
Nasdaq6d
Nektar Therapeutics Reports Stable Q3 Earnings for 2024
Nektar Therapeutics ( (NKTR)) has released its Q3 earnings. Here is a breakdown of the information Nektar Therapeutics presented to its investors. Nektar Therapeutics is a clinical-stage ...
ETF Daily News6d
Moloney Securities Asset Management LLC Sells 50,000 Shares of Nektar Therapeutics (NASDAQ:NKTR)
Nektar Therapeutics had a negative return on equity of 133.64% and a negative net margin of 190.09%. The business had revenue of $23.49 million for the quarter, compared to the consensus estimate ...